SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC - BROOKLYN IMMUNOTHERAPEUTICS ownership

BROOKLYN IMMUNOTHERAPEUTICS's ticker is BTX and the CUSIP is 114082100. A total of 53 filers reported holding BROOKLYN IMMUNOTHERAPEUTICS in Q3 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.

Quarter-by-quarter ownership
SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC ownership history of BROOKLYN IMMUNOTHERAPEUTICS
ValueSharesWeighting
Q1 2022$66,000
-60.0%
32,235
-18.7%
0.00%
-75.0%
Q4 2021$165,000
-64.7%
39,635
-21.2%
0.00%
-55.6%
Q3 2021$468,00050,3000.01%
Other shareholders
BROOKLYN IMMUNOTHERAPEUTICS shareholders Q3 2021
NameSharesValueWeighting ↓
Cypress Point Wealth Management, LLC 471,878$8,499,0006.04%
BALDWIN BROTHERS LLC/MA 44,116$795,0000.09%
DOWLING & YAHNKE LLC 15,806$285,0000.02%
INVERNESS COUNSEL LLC /NY/ 13,307$240,0000.01%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 15,000$270,0000.01%
Cutler Group LLC / CA 4,200$75,0000.00%
MetLife Investment Management, LLC 10,805$194,5980.00%
HAP Trading, LLC 13,900$64,0000.00%
METROPOLITAN LIFE INSURANCE CO/NY 8,272$148,9790.00%
Ameritas Investment Partners, Inc. 1,867$34,0000.00%
View complete list of BROOKLYN IMMUNOTHERAPEUTICS shareholders